Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by MAP2K2 and B2M mutations in melanoma.
Sign Up to like & getrecommendations! Published in 2019 at "Experimental and molecular pathology"
DOI: 10.1016/j.yexmp.2019.104260
Abstract: Although the treatment of metastatic melanoma has been significantly improved by both anti-BRAF/MEK and checkpoint immunotherapies, resistance to these treatment modalities remains a substantial clinical problem. Multiple clinical studies are addressing the optimal sequencing of… read more here.
Keywords: treatment; map2k2 b2m; braf mek; checkpoint ... See more keywords